NCT04526223Unknown不适用
Allogeneic HCT Outcomes in MF Patients Exposure to Ruxolitinib During Transplantation
xuna1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2017年4月20日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Time of neutrophils reconstruction
研究概览
简要总结
Increasing experience of Ruxolitinib pre-allo SCT and data concerning Ruxolitinib during transplantation
- Diagnosis MF(includ Post-ET,Post-PV,PMF,MDS/MPN with MF)
- With at least two month Ruxolitinib treatment prior to transplantation
- DAC+BF as myeloablative conditioning regimen
- CSA from day -3 and MMF from day +1 until day 28 ATG Neovii® at dose of 7.5mg/KG for mismatch donor
- received Rux at +6d in ASCT and continued to +60d
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-60 years old, gender is not limited;
- •Diagnosis MF(includ Post-ET,Post-PV,PMF) according to 2016 WHO
- •With at least two month Ruxolitinib treatment before transplantation
- •Informed consent of the patient or his legal representative
排除标准
- •HCT-CI score≥2
- •Woman who is pregnant or nursing
- •MPN Patients who have received allogeneic hematopoietic stem cell transplantation
研究组 & 干预措施
treatment group
Experimental
MF patients exposure to ruxolitinib during transplantation
干预措施: comprehensive treatment regimen (Other)
结局指标
主要结局
Time of neutrophils reconstruction
时间窗: 1 year
Neutrophils count≧0.5G/L without G-CSF
次要结局
- The incidence rate of GVHD(1 year)
研究者
xuna
doctor
Nanfang Hospital, Southern Medical University
研究点 (1)
Loading locations...
相似试验
终止
1 期
Upfront Ruxolitinib for Chronic Graft-vs-host DiseaseChronic Graft Versus Host DiseaseNCT06695507Children's Hospital Medical Center, Cincinnati1
进行中（未招募）
2 期
Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell TransplantHematopoietic Stem Cell Transplant (HSCT)Bronchiolitis Obliterans (BO)NCT04908735Children's Hospital Medical Center, Cincinnati7
招募中
不适用
Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia VeraMyelofibrosisSecondary MyelofibrosisPrimary MyelofibrosisNCT06516406IRCCS Azienda Ospedaliero-Universitaria di Bologna1,055
招募中
1 期
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to RuxolitinibMyelofibrosisNCT04485260Kartos Therapeutics, Inc.36
已完成
2 期
JAK2 Inhibitors RUXOLITINIB in Patients With MyelofibrosisMyelofibrosisNCT01795677French Innovative Leukemia Organisation78